Xbrane Biopharma to participate at Redeye Growth Day 2020

Corporate Information

English

News

Other Corporate Information

Xbrane Biopharma AB (publ) ("Xbrane" or "the Company”) represented by Martin Åmark, CEO, will participate at Redeye’s Growth Day 2020.

On June 2, at 5:30 PM, Martin Åmark, CEO, Xbrane Biopharma, will present the latest events and development in the Company at Redeye. The presentation will be live and can be followed at the below link,

https://www.redeye.se/live/growth-day-2020

Afterwards, the presentation will be available on Xbrane’s company page at Redeye Universe:

https://www.redeye.se/company/xbrane-biopharma.

About Us

Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane’s leading product Xlucane, a Lucentis® biosimilar candidate, addresses the €10.4b ophthalmic VEGFa inhibitor market. Xlucane is in phase III and marketing authorization is expected mid-2022. Xbrane has additionally four biosimilars in its pipeline targeting €8.7b in originator sales. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com.